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Several systemic diseases share clinical, pathologic and radiologic characteristics. This article
emphasizes similarities and differences in the clinical and chest radiographic manifestations of
six diseases with both pulmonary and renal abnormalities-Goodpasture's syndrome, Wegen-
er's granulomatosis, lymphomatoid granulomatosis, Churg-Strauss syndrome, systemic lupus
erythematosus, and scleroderma.
This article reviews and discusses the clinical, pathologic, and radiographic
features of a group of systemic diseases which share pulmonary and renal abnormali-
ties. Emphasized are similarities and differences in the clinical and chest radiographic
manifestations of Goodpasture's syndrome, Wegener's granulomatosis, lymphoma-
toid granulomatosis, Churg-Strauss syndrome, systemic lupus erythematosus, and
scleroderma. Wegener's granulomatosis, lymphomatoid granulomatosis, and Churg-
Strauss syndrome are each considered under one category of diseases with pulmon-
ary/renal pathology, the systemic granulomatous vasculitides. Systemic lupus erythe-
matosus and scleroderma belong to a group of disorders known as the connective
tissue diseases. However, all six of these diseases have in common the propensity to
present with pulmonary abnormalities which may provide problems in differential
diagnosis. It is our purpose to detail the characteristics of these diseases, particularly
the pulmonary findings, which aid in diagnosis and management.
GOODPASTURE'S SYNDROME
Goodpasture's syndrome is characterized by pulmonary hemorrhage with hemop-
tysis, diffuse alveolar filling on the.chest radiograph, anemia, and glomerulonephritis
(often rapidly progressive) [1-3]. Wilson and Dixon [6] extended this definition to
include the presence ofantiglomerular basement-membrane (anti-GBM) antibodies,
which are found in most patients with Goodpasture's syndrome [6,10,11]. Clinical
and experimental studies suggest that the disorder usually is caused by such
antibodies reacting with both glomerular and alveolar basement membranes [6,8,9].
While the catalyst is unknown, production of these antibodies is usually self-limited
[6], and the syndrome apparently is inactive when theantibody is notdetected [6,13].
Clinico-Pathologic Features
Early reports on Goodpasture's syndrome indicated a marked male predominance
of 9:1 [1], but more recent studies describe lower male-to-female ratios of 3.5:1 [14]
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the onset of the illness [3,15,16], while the remainder range in age up to 75 years [3].
In most cases, the initial symptom is hemoptysis which occurs at some pointduring
the course of the disease in 99 percent of cases [1,3]. Bouts of hemoptysis range in
severity from slightly blood-streaked sputum to massive hemorrhage [1]. In about
one-fifth of the patients, upper respiratory tract infections of a non-specific (viral)
nature precede the appearance of the syndrome [1]. Chills and fever occur acutely
with pulmonary hemorrhage but are not otherwise prominent. Substernal chest pain
occurs without relation to activity, although it can be aggravated by coughing.
Renal abnormalities may occur before pulmonary symptoms. In the Wilson and
Dixon study, 8 of 32 patients initially had renal abnormalities 0.2 to 13 months
before pulmonary symptoms [6]. Urinary findings, present on admission in over 80
percent of patients [3], include proteinuria, microscopic hematuria, and, less com-
monly, pyuria [1,3,6]. In 26 ofWilson and Dixon's patients (81 percent), renal failure
requiring dialysis occurred within one to 14 months of onset (mean 3.5 months) [6].
Anemia is universally present early in the disease [1,3]. In Benoit's review [1],
initial hemoglobin levels averaged 7.7 g/ 100 ml (range, 3.8 to 14.5), with the lowest
levels usually related to severe pulmonary hemorrhage. Theanemia is apparently not
hemolytic, although a decreased erythrocyte life span has been demonstrated [1].
Neither hemolysis nor jaundice is present.
Chest Radiographic Findings The radiographic appearance of Goodpasture's
syndrome (Figs. 1,2) is closely related to the distribution, volume, and time sequence
of pulmonary hemorrhage. Both interstitial and alveolar involvement occur [4].
Confluent densities are seen shortly after hemorrhage and may be indistinguishable
from hypervolemia associated with azotemia or from noncardiogenic pulmonary
edema of other origin. All these conditions produce rapid alterations in the chest
radiograph. Localized air space changes may progress to diffuse opacification within
hours, while complete clearing may occur during remission. However, accentuated
interstitial markings tend to persist in Goodpasture's syndrome after repeated
FIG. 1. Goodpasture's Syndrome-
Posteroanterior (PA) chest radiograph
shows characteristic acinar pattern.
.... .. .. . . .......
Heart, pulmonary vascularity, and
pleura are normal. Also note even
distribution of the alveolar process.
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FIG. 2. Goodpasture's Syn-
drome-PA chest radiograph,
unlike Fig. 1, shows predomi-
nantly lower lobe peripheral
opacification. This may be the
predominant pattern in many
patients with Goodpasture's syn-
drome.
episodes of bleeding due to the presence ofsiderophages in the interstitium [4,17]. If
the bleeding is of sufficient duration, permanent reticulonodular infiltrates develop,
resembling the appearance of idiopathic pulmonary hemosiderosis [4,18,19,20].
Generally, these changes are diffuse, but they may be localized. The superimposition
of fluffy alveolar densities on a reticulonodular background suggests recurrent
pulmonary hemorrhage.
In contrast to the pulmonary venous congestion and edema of left ventricular
failure, Goodpasture's syndrome demonstrates a predilection for perihilar involve-
ment while Kerley B lines and pleural effusions are not characteristic [4].
Diagnosis and Pathologic Findings Diagnosis of Goodpasture's syndrome de-
pends on presence of the characteristic glomerular lesions and anti-GBM antibodies,
together with evidence of lung hemorrhage in patients who typically present with
recurrent hemoptysis, dyspnea, and anemia [3,6].
Histologically, the renal abnormality in Goodpasture's patients is an actively
proliferating, often necrotizing, crescent-forming type ofglomerulonephritis [6]. This
is accompanied by variable, probably secondary, tubular alterations and interstitial
infiltrative processes.
Electron microscopic examination of glomeruli reveal widespread, irregular
thickening of the lamina rara interna [18] together with a poorly defined, mottled
increase in electron density along the central portion of the basement membrane in
the region of the lamina densa [3,9,11,12]. Thickening of the lamina rara interna,
ubiquitous in Goodpasture's syndrome, is seen also in other glomerular diseases such
as toxemia of pregnancy [3].
Etiology and Pathogenesis
The presence of anti-GBM antibodies is clearly involved in the glomerulonephritis
and probably the pulmonary hemorrhage ofGoodpasture's syndrome [6,21,23]. The
mechanism mediating this damage, however, is not known although environmental
factors are thought to be instrumental in triggering their production [6]. For
example, antigens such as the influenzae A2 virus might cause the production of
antibodies that cross react with the basement membrane structures [21]. Many
patients have a history of preceding viral syndromes, either of the upper respiratory
tract or gastrointestinal tract. Infectious agents or chemical substances such as
hydrocarbon solvents might uncover or alter some self antigens so that they become
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noxious stimuli (infectious or chemical) might alter the anatomic integrity ofthe lung
and expose basement membrane antigens, which normally are sequestered from the
circulation [6].
Therapy and Prognosis
The prognosis for Goodpasture's syndrome is generally poor. Fifty of the 52
patients in Benoit's 1964 review died, 23 of renal failure and 27 of lung hemorrhage
[1]. In Wilson and Dixon's study [6], in which the diagnosis was based on the
presence ofcirculating anti-GBM antibodies, 28 of32 patients developed renal failure
and over one-half died within one year of diagnosis.
The most promising therapy includes plasmapheresis and immunosuppressive
therapy with cyclophosphamide and prednisone [13,25-29]. Because of the lack of
controlled studies, the exact effects of this combined therapy are not clear. Since
production of anti-GBM antibodies may be short-lived, plasma exchange should
reduce damage to the glomerulus by lowering the levels ofcirculating antiglomerular
basement membrane antibody. Lockwood et al. [13] reported on seven patients
treated with plasma exchange, cytotoxic drugs, and corticosteroids. Renal function
improved in three who were not already receivingdialysis at the initiation oftherapy.
Five patients had pulmonary hemorrhage, which appeared to respond to therapy.
These investigators reported that although the fall in anti-GBM antibody titer was
variable, there was also depletion offibrinogen and complement. They believed that
the reduction of the latter two substances could have been important therapeutically.
Swainson et al. [29] noted a rebound increase in anti-GBM antibody levels following
periods ofplasma exchange. They concluded that plasmaexchange was only effective
in substantially reducing the circulating amounts of complement or fibrinogen when
performed on consecutive days. The rapid rise in concentrations after exchange
reflects rapid turnover and distribution from extravascular pools.
In general, plasma exchange maybe useful in the early treatment ofsevere forms of
Goodpasture's syndrome by controlling pulmonary hemorrhage and preventing
irreversible renal damage from the high anti-GBM antibody levels. However, the
removal of anti-GBM antibodies does not lead to recovery of renal function.
Furthermore, there is considerable variation in the amount ofreduction ofanti-GBM
levels in the serum produced by serial plasma exchange and immunosuppression. A
controlled clinical study is urgently needed to justify the considerable expense of
extensive plasma exchange before its wider use can be encouraged.
SYSTEMIC GRANULOMATOUS VASCULITIDES:
WEGENER'S GRANULOMATOSIS
Wegener's granulomatosis has a distinctive clinico-pathologic triad of necrotizing
granulomatous vasculitis ofthe upper and lower respiratory tracts, glomerulonephri-
tis, and variable degrees od disseminated small vesselvasculitis [7,30-32]. A localized
form of Wegener's limited primarily to the respiratory tract has been reported [7,33]
but probably represents an early stage that, if not treated, eventually would involve
the kidney and become a generalized Wegener's. However, some patients may have a
"forme fruste" of the disease that never disseminates [7].
Clinico-Pathologic Festures
Wegener's granulomatosis can occur at any time, but the average age ofonset is 40
years. The disease occurs in males twice as frequently as in females [7].
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Initially, clinical presentations vary widely among patients, but generally are
related to the upper respiratory tract. Typical findings include rhinorrhea, severe
sinusitis, and, frequently, nasal mucosal ulcerations and otitis media, usually
secondary to blockage of the eustachian tube resulting from upper airway disease [7].
Some patients present with primary middle ear disease, and hearing lossmay be the
initial complaint [7]. Fever occurs in almost 80 percent ofcases, but in approximately
one-half, it is secondary to a detectable infection, usually of the paranasal sinuses
[30].
Pulmonary symptoms include cough, hemoptysis, and, less frequently, chest
discomfort [7,30]. Pulmonary function studies generally show loss of lung volumes
with a restrictive ventilatory defect in association with significant parenchymal
lesions [2]. More than 50 percent of patients with Wegener's also have an obstructive
ventilatory abnormality that cannot be related to cigarette smoking [2]. In patients
with obstructive changes, granulomatous lesions that have blocked an airway may be
found during fiberoptic bronchoscopy. The presence of these lesions also may be
suggested by abnormalities found on flow-volume curves.
Renal disease is the sine qua non of generalized Wegener's granulomatosis. Prior
to the use of cytotoxic agents as therapy in this disorder, most patients succumbed to
renal disease, with a mean survival of five months from the onset ofclinically evident
renal involvement [7]. The urinary findings in generalized Wegener's are those of
acute glomerulonephritis with hematuria, red blood cells casts, and proteinuria.
Any of the other organ systems involved in Wegener's may also be the focus of
initial complaints. Arthralgias frequently are part of the presenting symptomatology,
as are other generalized manifestations of systemic inflammatory disease, such as
fatigue, malaise, anorexia, and weight loss [7,30].
Wegener's granulomatosis presents a characteristic complex of laboratory find-
ings. The mild anemia of subacute or chronic diseases is seen frequently, as is mild
leukocytosis. Thrombocytosis (up to 1,000,000 platelets/mm3) can be present and
probably represents an acute reaction [7]. Bentonite flocculation test findings are
mildly elevated in about 50 percent of patients, whereas results of antinuclear
antibody and lupus erythematosus (LE) cell preparation tests are uniformly negative.
Whole complement levels are normal or mildly elevated. Mild hyperglobulinemia,
particularly involving the serum immunoglobulin A fraction, occurs commonly [34].
Almost all patients have strikingly elevated erythrocyte sedimentation rates, usually
100 mm/hour or more (Westergren method) [7].
Chest Radiographic Manifestations The pulmonary infiltrates of Wegener's
granulomatosis are heterogeneous, and may be any size, shape, or lobar location
(Figs. 3-5) [2,7,30-43]. The most characteristic, although not the most common,
patterns are solitary (Fig. 5) or multiple nodular densities (Figs. 3,4) or infiltrates,
either poorly defined or sharply circumscribed [2,30]. These opacities vary in size
from less than 1 cm to greater than 9 cm [30,36,37]. The infiltrates may be unilateral,
but usually involve both lungs [37]. Unilocular or multilocular cavitation with
irregular walls is common [30,36,37], and occasionally air-fluid levels are found [38].
Some investigators have described these cavities as thick-walled [36], but others [37]
maintain that thin-walled cavities are the rule. They suggest that the walls appear
thick on plain chest films due to infiltration of the surrounding lung. The infiltrates
may be quite transient with one disappearing in one lung field and other appearing in
a different location [37].
Atypical radiographic manifestations of Wegener's include focal areas ofcollapse
adjacent to infiltrates [37] and mediastinal lymph node enlargement [38]. The
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FIG. 3. Wegener's Granulomatosis-PA
chest radiograph with multiple, large con-
fluent nodules. No cavitation, adenopathy,
or pleural effusion is present.
combination of hilar and-mediastinal adenopathy on the chest radiograph should
suggest an alternate diagnosis [2]. Other occasional signs include bronchopleural
fistula; narrow areas in the larger airways, which may lead to lobar collapse [39]; and
pleural thickening and pleural effusions [2,36]. Maguire et al. [39] recently reviewed
31 pathologically proven cases of Wegener's granulomatosis and identified so-called
unusual radiographic findings in 16 patients. These included endobronchial disease
resulting in atelectasis of either a lobe or a complete lung and pleural disease with
thickening or effusion, which was massive in some cases.
Diagnosis and Pathologic Findings An important aspect of Wegener's granulo-
matosis is its pathologic and clinical similarity to a variety of other disorders
characterized by granulomatous inflammation, vasculitis, or both [7,30]. These
:;. .....
FIG. 4. Wegener's Granulomatosis-PA
chest radiograph shows three nodules. There
is a suggestion of cavitation in the right upper
lung nodule which was confirmed by tomog-
raphy.
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FIG. 5. Wegener's Granulomatosis-PA chest
radiograph in patient with hemoptysis. There is a
solitary, irregular patchy density in the anterior
segment of the left upper lobe. The apparent cavity
represents compressed normal lung.
include vasculitic disorders such as polyarteritis nodosa; hypersensitivity vasculitis;
the spectrum of connective tissue diseases; granulomatous diseases, such as sarcoido-
sis and midline granuloma; mixed granulomatous and vasculitis diseases, such as
allergic granulomatosis; infectious granulomatous diseases, such as tuberculosis,
leprosy, and fungal disease; Goodpasture's syndrome; and a variety of neoplasms
accompanied by a granulomatous or vasculitis inflammatory response [7].
Open lung biopsy is the procedure of choice in approaching the pulmonary
infiltrates of Wegener's granulomatosis. The outstanding pathologic feature in all
cases is the presence of inflammatory masses (.5 to 5 cm) within the parenchyma of
one or both lungs [44]. Generally, the masses are few and sharply circumscribed on
gross examination. Microscopically, they consist of necrotic areas surrounded by
zones of granulation tissue.
The earliest lesion in the kidney is a focal and segmental glomerulitis [7,45]. Ifnot
treated properly, the lesions progress to a fulminant, necrotizing, and proliferative
glomerulonephritis, and eventually can lead to renal failure. At very early stages,
glomerulitis may go undetected because the urinary sediments and renal function
may be normal. Therefore, percutaneous renal biopsies are recommended when there
is a high index of suspicion of Wegener's, even when the urinary sediments are
normal [7]. Renal biopsies not only aid in establishing a diagnosis, but also serve to
monitor response to therapy as measured by subsequent biopsies.
Etiology and Pathogenesis
The etiology of Wegener's is unknown, although hypersensitive reaction to an
unidentified antigen is strongly indicated [31]. Circulating immune complexes occur
during the active process [46], and immune reactants and complex-like deposits have
been seen in some renal biopsies of patients with Wegener's granulomatosis and
active glomerulonephritis [31,30,45]. The role of these immune complexes in the
pathogenesis of the disease is not known.
Therapy and Prognosis
Untreated, Wegener's granulomatosis rapidly pursues a fatal course with a mean
survival time of five months in most cases [47,48]. Eighty-two percent ofpatients die
within one year and more than 90 percent within two years. Although corticosteroids
increase mean survival to 12.5 months [49], the long-term prognosis is not signifi-
503cantly altered by this therapy, especially in patients with clinically apparent renal
disease.
The current drug of choice in treating Wegener's granulomatosis is cyclophospha-
mide [2,7,30,31,34]. This drug produces long-term remission in most patients. The
drug is administered orally or, in cases of rapidly progressive disease, intravenously.
A clinical reponse is usually seen after one to three weeks of therapy. The dose of
cyclophosphamide must be monitored continually and adjusted to keep the white
blood cell count above 3,000 cells per mm3 [2,31].
In patients who cannot tolerate cyclophosphamide because ofsevere leukopenia or
hemorrhagic cystitis, or in young women who are not willing to accept the ovarian
damage associated with cyclophosphamide, azathioprine is an alternative cytotoxic
agent. However, generally experience has shown that azathioprine is not as effective
as cyclophosphamide [2,31].
SYSTEMIC GRANULOMATOUS VASCULITIDES:
LYMPHOMATOID GRANULOMATOSIS
Lymphomatoid granulomatosis is a systemic disease characterized byan angiocen-
tric, angiodestructive, and lymphoreticular granulomatous vasculitis primarily ofthe
lungs, but also frequently involving the kidneys (45 percent), skin (45 percent), and
central nervous system (20 percent) [2,41,42,50,51]. Although any organ system can
be involved, the spleen, lymph nodes, and bone marrow usually are spared. This
disorder resembles an indolent lymphoma, and, in many instances, it progresses to an
atypical disseminated lymphoproliferative disease (Fig. 8) [2,41,50,51].
Clinico-Pathologic Features
The male-to-female ratio is about 2:1, and most patients are in early middle age
[41,51]. Lung involvement is a sine qua non of lymphomatoid granulomatosis and
usually is manifested as multiple nodular infiltrates of various sizes that tend to
cavitate [2,41,50,51]. Most patients present with chest symptoms (cough and short-
ness of breath) or systemic complaints (fever, weight loss, malaise) or both. Pre-
senting complaints in 142 cases are listed in Table 1 [50].
Most patients have a normal or only slightly reduced hematocrit. In Katzenstein's
series [50], the presenting leukocyte count was normal in 50 percent, elevated in 30
TABLE 1
Presenting Complaints in 142 Patients with Lymphomatoid Granulomatosis*
Total Percent
Fever 82 57.7
Cough 79 55.6
Malaise 50 35.2
Weight loss 49 34.5
Shortness of breath 41 28.9
Neurological 30 21.1
Chest pain 19 13.4
Arthralgias 9 6.3
Myalgias 4 2.8
Gastrointestinalt I 4 2.8
Asymptomatic 4 2.8
*From Katzenstein et al. [50]
tlncludes nonspecific gastrointestinal complaints such as nausea and vomiting, diarrhea, and ab-
dominal pain
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percent (range, 9,000-38,000), and reduced in 20 percent (range, 1,200-3,900). A
relative lympocytopenia was noted in 33 percent and lympocytosis in 6 percent.
Serum immunoglobulins were normal in 53 percent of cases and nonspecific
increases, usually in IgG or IgM, were seen in the remainder [50].
Chest Radiographic Manifestations The chest radiographic manifestations of
lymphomatoid granulomatosis (Figs. 6-8) depend in part on the duration of the
disease. Lesions mayappear and disappear without relation to therapy, as also occurs
in Wegener's granulomatosis [2,31,41]. The pulmonary lesions predominate in the
lower lung fields peripherally (Figs. 7,8A) and are usually bilateral [41]. Typically,
the early lesions present as multiple, bilateral, ill-defined densities [2,50]. Later, they
become better defined and resemble nodular metastases ofvarious malignancies (Fig.
8B) [2,41]. The lesions also may coalesce (Fig. 6B), especially in the lung bases, and
resemble a mass-like or pneumonic process [2]. Cavitation was seen in 30 percent of
the original patients studied by Leibow et al. [51]. Hemorrhage secondary to
cavitation was the cause of death in 14 percent of the 40 patients in this study [51].
Hilar adenopathy is unusual in lymphomatoid granulomatosis and occurs only in a
few patients whose disease ultimately pursues the course of lymphoma [41]. Pleural
effusions.may or may not be present (Fig. 7).
Diagnosis and Pathologic Findings The definitive diagnosis of lymphomatoid
granulomatosis is made histologically. Plasma cells, lymphocytic cells, and large
"atypical" mononuclear cells in various stages of maturity infiltrating perivascular
tissue are characteristic [52]. Occlusion by infiltration of the vessels and subsequent
tissue necrosis are frequent findings. With peripheral nerve involvement, the infiltrate
is seen surrounding the nerve, and spotty demyelination is present. When the skin is
involved, the small vessel destruction with a lymphoreticular infiltrate is most often
seen surrounding the dermal appendages [52].
This disorder is often confused clinically with Wegener's granulomatosis. How-
ever, granulomata are less copious and less distinct, and the vasculitis is remarkable
FIG. 6A. Lymphomatoid granulomatosis-PA
chest radiograph with irregular nodular-like densities
in the right mid lung and also at the base of the left
lung. A smaller density is noted in the right upper
lung zone.
FIG. 6B. A lateral radiograph confirms
nodular aspect of the lesions. In the middle
lobe, the nodules appear confluent. The hilar
structures are normal.506 MATTHAY ET AL.
FIG. 7. Lymphomatoid granulomatosis-
PA radiograph reveals obscuration of the left
hemidiaphragm and linear densities left lower
lobe. A lateral decubitus film confirmed a
small free effusion. Also note the indistinct
mass density left upper lung zone.
in that it is not the characteristic leukocytoclastic or fibrinoid necrotic type seen in
Wegener's and other systemic vasculitides [2,31,41]. In contrast, there is an angiotro-
phic invasion of blood vessels of various sizes with a bizarre cellular infiltrate. Blood
supply through the involved vessels is compromised, and infarction and necrosis
occur as in other vasculitides.
In addition to its characteristic histopathologic features, lymphomatoid granulo-
matosis differs from Wegener's in several other-ways-[2-]. Sinus and upper airway
FIG. 8A. Lymphomatoid granulomatosis-
PA chest radiograph shows bibasilar large lung
nodules. Right open lung biopsy revealed lym-
phomatoid granulomatosis.
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FIG. 8R. PA chest radiograph done almost three
years later, after therapy with corticosteroids and
chlorambucil, shows clearing of the bibasilar densi-
ties and appearance of at least two new lesions, one
in the left mid lung zone, the other in the lower one-
third of the right lung. The left-sided lesion contains
a distinct air bronchogram. Also note the enlarged
cardiac silhouette and likely third new lesion at left
heart border. Open lung biopsy of the new large left
lung mass revealed lymphoma.PULMONARY RENAL SYNDROMES-A REVIEW
involvement is unusual in lymphomatoid granulomatosis. In addition, renal involve-
ment in lymphomatoid granulomatosis is a diffuse nodular infiltrate of the renal
parenchyma with a characteristic cellular infiltrate in contrast to the necrotizing
glomerulonephritis seen in Wegener's granulomatosis [7,41,47,51]. Leukopenia and
anergy before therapy are rare in Wegener's but are seen frequently in lymphomatoid
granulomatosis [3,31]. Also, contrary to the condition of patients with Wegener's
granulomatosis [30,31,34], the erythrocyte sedimentation rate may be normal in some
patients during disease activity [47].
Etiology and Pathogenesis
The etiology of lymphomatoid granulomatosis is unknown. It may be an acquired
abnormality ofthe lymphocyte in a susceptible host, such as Sjogren's syndrome [53].
Evidence for this includes absent delayed hypersensitivity as demonstrated by non-
reactivity to skin test antigens and the response of the lung lesions to the corticoste-
roids [52]. As in Sjogren's syndrome, lymphomatoid granulomatosis can terminate in
a neoplastic disease [51,52].
Other disease, such as lymphoma and mycosis fungoides, can have years of
symptoms with a biopsy showing nonspecific lymphoid and plasma cell infiltrates
before it assumes the usual features of a neoplastic disease. Renal homotransplanta-
tion can be followed by lymphoreticular proliferation with involvement ofthe central
nervous system [54-56]. Antigenic exposure in an immunosuppressed host mayalter
the cell membrane and produce an auto-immune disease [51,57-63]. With continued
immunosuppression, neoplastic disease may result [64,65].
Therapy and Prognosis
Untreated, lymphomatoid granulomatosis is usually rapidly progressive and fatal
[31]. Death is often related to pulmonary or central nervous system complications
[51]. Nevertheless, preliminary reports indicate that a relatively high rate of long-
term remissions can be achieved if patients are treated early with cyclophosphamide
and corticosteroids in the same regimen as used for Wegener's granulomatosis [66].
SYSTEMIC GRANULOMATOUS VASCULITIDES:
ALLERGIC ANGIITIS AND GRANULOMATOSIS
(CHURG-STRAUSS STYNDROME)
Churg and Strauss [67] in 1951, and Rose and Spencer [68] in 1957, described an
uncommon granulomatous inflammation and vascular necrosis primarily involving
the heart, lungs, skin, nervous system, and kidneys. This entity, commonly referred to
as allergic angiitis and granulomatosis, occurs primarily in patients with an allergic
background or asthma or both.
Clinico-Pathologic Features
In 30 cases of the Churg-Strauss syndrome reported by Chumbley [69], 21 were
men and nine were women. Ages ranged from 15 to 69 years; the average was 47. The
mean duration of asthma was eight years. It began at the same time as the
manifestations ofsystemic vasculitis in six cases, but preceded it in all others. Allergic
rhinitis occurred in 21 of the 30 cases (70 percent) [69].
Most patients have a fever at some point in their clinical course [67,69]. Anemia
and weight loss are common, as is leukocytosis and elevation of the erythrocyte
sedimentation rate [69]. Peripheral blood eosinophilia is seen at some time in each
507case [69]. The degree ofeosinophilia and erythrocyte sedimentation rate elevationare
good indicators of disease activity [69].
Chest Radiographic Manifestations Chest radiographic abnormalities range
from transient patchy densities to massive bilateral nodular infiltrates without
cavitation to diffuse interstitial disease (Fig. 9) [69-71]. New lesions may appear
while older ones are disappearing; some remain stable after an initial period of
improvement, while others stabilize without improvement [71]. Complete radio-
graphic regression of a widespread active pulmonary process is sometimes seen with
corticosteroids [72].
Diagnosis and Pathologic Findings Histologically, the lungs typically show
fibrinoid, necrotizing, and eosinophilic granulomatous lesions which frequently
involve the pulmonary arteries [71]. In about one-half of their cases, Churg and
Strauss [67] found parenchymatous lesions in the form of an extensive pneumonic
process involving septa and alveoli. In the acute stage, exudate in the lungs had a
predominance of eosinophilic leukocytes mixed with giant cells. Histologic evidence
of bronchial asthma (hyalinization of basement membrane, increased mucus secre-
tion, and eosinophilic infiltration of the bronchial walls) was present in most cases,
but generally was not very marked [67].
Allergic granulomatosis (Churg-Strauss syndrome) strongly resembles classic
polyarteritis nodosa with some obvious distinguishing features. Churg-Struass
syndrome almost invariably is associated with an allergic diathesis, particularly
severe asthma[31]. Reports ofthe incidence ofasthma with polyarteritis nodosa have
ranged from 4 percent to as high as 54 percent [69]. In general, unlike classic
polyarteritis nodosa in which pulmonary abnormalities are rare, lung involvement is
a sine qua non of the Churg-Strauss syndrome. Also, this syndrome is characterized
by high levels of peripheral eosinophilia (usually higher than 1,500 per mm3),
eosinophilic tissue infiltration and granulomatous reactivity [31,67-69]. In contrast,
the predominant cellular infiltrate in polyarteritis nodosa is the neutrophilic leuko-
cyte [69]. In addition to the fibrinoid necrosis of small and medium-sized muscular
arteries that is the hallmark of classic polyarteritis nodosa, a substantial degree of
FIG. 9. Churg-Strauss syndrome-PA
chest radiograph with scattered subsegmental
infiltrates in both lungs. The subcutaneous air
in left superior-lateral chest is secondary to
closed lung biopsy. There is no evidence of
I hilar adenopathy or pleural disease.
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involvement of small vessels, such as capillaries and venules, is present in Churg-
Strauss syndrome [31].
The "overlap syndrome" of the systemic vasculitides combines many features that
are characteristic of classic polyarteritis nodosa, other systemic vasculitides of the
small and medium-sized vessels, such as allergic angiitis and granulomatosis (Churg-
Strauss syndrome), and the small-vessel hypersensitivity vasculitides [2,31]. Large
and small arteries, as well as capillaries and venules, may be involved in the vasculitis
process. One patient may have features that would be considered characteristic, or
even pathognomonic, of either classic polyarteritis nodosa or allergic granulomato-
sis. The "overlap syndrome" is a multisystem disease with the associated protean
clinical manifestations. The same patient may have small-vessel involvement (arteri-
oles, capillaries, and venules), as well as the classic small-and-medium-sized muscular
artery involvement with characteristic angiographically demonstrable small aneu-
rysms. A history of allergy, peripheral eosinophilia, eosinophilic tissue infiltration
[2], granulomatous reactions, and lung involvement described for Churg-Strauss
syndrome may all be seen in the same patient, or one or more ofthese may be seen to
the exclusion of the others [31]. This syndrome is the most difficult to classify.
Therapy and Prognosis
Well controlled experience with therapy for the Churg-Strauss syndrome is
lacking. Chumbley and co-workers treated 27 of their 30 patients with prednisone
[69]; most received 40 to 60 mg daily, others 100 to 120 mg daily. Fifteen of these
patients died, three within a year after symptoms of vasculitis appeared [69]. The
interval from onset of signs and symptoms of vasculitis to death ranged from 6
months to 15 years, average 4.6 years. Cyclophosphamide and azathioprine therapy
have theoretical rationale since they are effective in treating another necrotizing
vasculitis, Wegener's granulomatosis. However, experience with these agents is
minimal [69].
CONNECTIVE TISSUE DISEASES
The connective tissue (collagen vascular) diseases are a heterogeneous group of
chronic inflammatory and immunologically mediated disorders. They share certain
clinical characteristics including inflammation ofjoints, serosal membranes, connec-
tive tissue, and blood vessels in various organs [2]. The lung is particularly vulnerable
to this group of diseases because of its abundant vasculature and connective tissue
[2]. Two of the classic collagen vascular diseases, systemic lupus erythematosus
(SLE) and scleroderma, frequently involve both the lungs and the kidneys.
SYSTEMIC LUPUS ERYTHEMATOSUS
Systemic lupus erythematosus is a multisystem disease associated with auto-
immune antibodies and circulating immune complexes. It is characterized by
widespread inflammatory changes in connective tissues, vessels, and serosal surfaces.
In contrast to rheumatoid arthritis (RA), another connective tissue disease, renal
involvement is common in SLE, and, together with central nervous system disease
and infections, often determines survival of these patients [2].
Although infections are the most common cause of infiltrates in the lungs of
patients with SLE, many patients develop infiltrates apparently independent of
infection [2,73-90]. In fact, the lungs and pleura together are affected more fre-
quently in SLE than in the other connective tissue diseases, the incidence varying in
reported series from 50 to 70 percent [2.73,90-96].
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Pathologically, 90 to 100 percent of patients with SLE have some microscopic
renal abnormality. The nephrotic syndrome and uremia are the clinical features.
With use of the light microscope, patterns of minimal change, focal proliferative
glomerular lesions (33 percent), membranous glomerulopathy(15 percent), or diffuse
proliferative glomerulonephritis (50 percent) may be observed. Immunofluorescence
findings are variable, but nodular deposits ofvarious immunoglobulins, complement
components, fibrin, and DNA may be seen in mesangium and capillary loops. The
prognosis of SLE is considerably worsened with increasing degrees of renal involve-
ment. Corticosteroids are useful in controlling the extrarenal manifestations of the
disease but cytotoxic drugs and anticoagulants are sometimes necessary to control
severe renal disease.
The clinical manifestations of pleuropulmonary involvement vary but usually
include cough with or without sputum, dyspnea, and pleuritis [2,73]. Pleural disease
is more frequently painful in SLE than RA, and is often associated with fever [2].
Rarely, patients present with mild or overwhelming hemoptysis [79,97-99], and
pulmonary involvement may be the initial feature of SLE [73,77], as well as one
associated with an exacerbation of previously recognized disease [2].
Hunninghake and Fauci have classified the chest radiographic features ofprimary
pleuropulmonary disease in SLE under six separate categories [2]. Frequently, more
than one of these entities is present in an individual patient. Figures 10 and 11
provide typical examples of chest radiographic abnormalities.
(1) Pleuritis and/or Effusion Pleuritis and/or effusion are the most common
pleuropulmonary abnormalities in SLE and are probably present at some stage ofthe
disease in at least 50 to 75 percent of patients (Fig. 10) [96]. Frequently painful,
pleural disease is often associated with exacerbation of the underlying disorder.
Winslow and co-workers [96] stressed the importance of pleuritis as an early
manifestation in the diagnosis of SLE. Pleural effusion occurred in 42 of their 57
cases. Although usually bilateral and small, these pleural effusions may be massive
[2,91,93,100]. The pleural fluid in SLE is usually an exudate with protein in excess of
3 gm per 100 ml. As in RA, concentrations ofcomplement aregenerally depressed in
the effusion [2]. However, in contrast to RA, pleural fluid glucose concentrations are
not markedly depressed [101], and the total leukocyte count is usually less than in RA
FIG. 10. Systemic lupus
erythematosus-A PA chest
radiograph reveals promi-
nence of the cardiac shad-
ow; echocardiography con-
firmed a moderate-sized
pericardial effusion. Also
note the large left pleural
effusion.
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FIG. I IA. Systemic lupus erythe-
r '-t ; matosus-A PA chest radiograph
shows reticulonodular densities in both
lower lung zones. An open lungbiopsy
consistent with "lupus pneumonitis";
no evidence of infection was found.
[102]. In addition, lupus erythematosus cells are occasionally found [2,103]. When
pleural effusions are present in patients with SLE, it is prudent to obtain samples of
this fluid for diagnostic studies because there may be co-existing infection. When
another underlying process has been excluded, the patient should be started on
corticosteroid therapy, or the current dosage of cortocosteroids should be increased
[2].
(2) Atelectasis Atelectasis, usually in the bases and situated peripherally, is
commonly seen on chest radiographs in patients with SLE [73,75-90]. The basilar
infiltrates frequently are associated with pleuritis, effusion, and/or diaphragmatic
dysfunction [104]. The development of basilar atelectasis is analogous to that
occurring after abdominal surgery; many of these patients have prolonged pleural
pain and splinting [2]. In numerous cases dyspnea and pulmonary function abnor-
malities are disproportionate to the chest radiographic changes.
(3) Uremic Pulmonary Edema Uremic pulmonary edema is readily established
by the presence of a markedly increased concentration of blood urea nitrogen. The
chest radiographic findings include fluffy acinar infiltrates that are more pronounced
in the perihilar areas and the lower lungzones [2]. Pleural effusion may or may not be
present.
(4) Acute Lupus Pneumonitis Acute lupus pneumonitis is a well-recognized
manifestation of SLE [73,82]. The diagnosis, however, is one ofexclusion since this
entity may be mimicked by atelectasis, uremic pulmonary edema, and secondary
FIG. IIB. An AP chest radiograph
taken two weeks later during corti-
costeroid therapy shows further exten-
sion of the parenchymal changes and a
probable left pleural effusion. At post-
mortem, focal areas of hemorrhage
and cytomegalic virus were identified.
511infections [2]. These lesions usually appear on chest radiographs as poorly defined
areas of increased density or extensive unilateral or bilateral acinar infiltrates (Figs.
11 A,B) [73,77-79,82]. Associated findings include cardiomegaly and pleuritis with or
without effusion. Patients with acute lupus pneumonitis characteristically are
extremely ill with severe dyspnea, a nonproductive cough, temperature of
100-1040F., tachypnea, and hypoxia [72,82]. There is no evidence of infection and
antimicrobial drugs are ineffective. Although most ofthese patients respond dramat-
ically to corticosteroids alone, some have improved only after the addition of
cytotoxic agents such as azathioprine [73,77,79]. Despite adequate therapy and
clinical improvement of the acute disease, many individuals experience recurrent
episodes of pneumonitis and frequently have residual restrictive lung disease of
varying severity [81,82,85,105-107]. The underlying pathology in this disorder is
unclear because most histologic studies have been performed either postmortem or
after therapy with corticosteroids. Histologic alterations include acute vasculitis,
hemorrhage, interstitial pneumonitis, and other nonspecific changes [73,78,108,109].
(5) Diffuse Interstitial Lung Disease Diffuse interstitial lung disease [63] is
significantly less common than the other pleuropulmonary abnormalities of SLE.
Eisenberg and co-workers [86] reported 18 SLE patients whose chest radiographs
demonstrated diffuse reticulonodular, interstitial infiitrates which were located
predominantly in the lower lung zones. These investigators noted that the frequency
of these lesions in their outpatient clinic was less than 3 percent [86]. Pulmonary
symptoms were dyspnea, a non-productive cough, and pleuritic chest pain. Physical
findings included poor diaphragmatic movement and basilar rales. Clubbingwas not
a feature in these patients. Pulmonary function studies showed a restrictive ventila-
tory defect with loss of volume, decreased diffusing capacity for carbon monoxide,
and hypoxia. Some of these patients responded favorably to corticosteroids [86].
(6) Diaphragmatic Dysfunction Diaphragmatic dysfunction with loss of lung
volume only recently has been described as an SLE abnormality [2,104]. However,
elevated diaphragms with "'sluggish" movement and loss of lung volume on chest
radiographs have been noted in previous studies [81,105,110]. Although fixation of
the diaphragms by pleural adhesions was not ruled out conclusively in these studies,
the etiology of this disorder is now believed to be diffuse myopathy affecting the
diaphragmatic muscles. In addition to decreased lung volumes and diffusing capac-
ity, these patients generally have reduced values for lung elastic recoil pressures at
total lung capacity and decreased maximal transdiaphragmatic pressures [2]. An
interesting clinical feature of this disorder is dyspnea in the supine position, a
symptom associated with diaphragmatic paralysis [2,111]. Although the natural
history of diaphragmatic dysfunction is not entirely clear, the restrictive ventilatory
defect is reported to have remained static during periods of four to six years [104].
Therapy and Prognosis
As noted, pleuritis, acute lupus pneumonitis, and interstitial lung disease all
warrant therapy with corticosteroids [2,73,77,79,86]. Although no controlled clinical
trials are available, generally the response to this therapy is favorable [2,73].
At least 50 percent of the pleuropulmonary abnormalities in SLE are secondary to
an infectious process [2,82]. Because infections and renal disease are an important
cause of death in such cases, it is critical to obtain appropriate cultures and to
perform histopathologic studies.
Pleural effusions and pulmonary infiltrates also are seen in approximately 50
percent of cases of drug-induced, SLE-like syndromes [2,112-117]. In fact, the
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incidence of pleuropulmonary abnormalities in the drug-induced disorder is second
only to that of diffuse arthralgias and myalgias, which occur in 75 to 90 percent of
patients with this disease. In contrast to cases of idiopathic SLE, once the nature of
this disorder is recognized and the offending agent is discontinued, the prognosis,
with few exceptions [118], is excellent [2].
PROGRESSIVE SYSTEMIC SCLEROSIS (SCLERODERMA)
Progressive systemic sclerosis [2,119-146] is a multisystem disease of unknown
etiology characterized by varying degrees of vascular change and fibrosis and
inflammation of skin and internal organs. The skin, gastrointestinal tract, muscu-
loskeletal system, kidneys, heart, and lungs are affected frequently [2,119,120].
Although the cutaneous features may dominate the clinical picture, it is the visceral
involvement that determines survival.
Among the visceral organs involved in scleroderma, pulmonary disease is second
only to esophageal involvement [119]. The true incidence of pulmonary involvement
is difficult to determine; however, chest radiographic abnormalities have been
described in up to 25 percent ofcases [119-121]. Pulmonary symptoms occur at some
time during the course of the illness in 50 percent of patients [119-121]. In one series
utilizing pulmonary function tests, abnormalities were present in 21 of 22 patients
[119]. Interstitial fibrosis is found at postmortem examination in nearly all cases
[120,126-1361. In one postmortem study of 196 cases [120], pulmonary fibrosis was
found in 77 percent, pulmonary vascular disease in 30 percent, and pleural disease in
32 percent.
Clinico-Pathologic Features
The majority of patients are affected in their fourth through sixth decades, and this
disease occurs three times more frequently in females than in males [119,120]. The
most prominent symptoms of pulmonary involvement are dyspnea and, less com-
monly, acough, which may be slightly productive [119,120]. Frequently there are fine
basilar rales and limited expansion of the chest [119]. Signs of cor pulmonale may
appear as a result of pulmonary vascular and interstitial disease. Renal involvement
may be extensive, and complications ofrenal disease ultimately may cause the demise
of the patient. Raynaud's phenomenon, often with trophic finger changes, occurs in
80 to 90 percent of patients and may precede other systemic involvement by years
[122,123]. Initial laboratory findings may be nonspecific. Fifty percent of patients
have hyperglobulinemia, and positive antinuclear antibodies occur in 50 to 60
percent, often in a nucleolar or speckled pattern [124].
Sackner and co-workers [121] noted increased pulmonary vascular resistance in all
patients who underwent cardiac catheterization. In about one-half of these patients,
the increased pulmonary vascular resistance was slight and did not produce clinical
or radiographic signs ofright ventricular hypertrophy. In the remainder, pulmonary
hypertension was accompanied clinically by signs of right ventricular hypertrophy
and right ventricular failure [121,127].
Pulmonary function abnormalities include a restrictive pattern with reduction of
vital capacity [119-121] and reduced lung compliance. A reduced diffusing capacity
for carbon monoxide is often theearliest abnormality noted and may be present prior
to recognized chest radiographic abnormalities [126]. Recently, Guttadauria and
colleagues [137] noted that 19 of 45 patients (42 percent) with scleroderma had
evidence of small airways disease on pulmonary function tests.
Chest Radiographic Findings The most common abnormality on the chest
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FIG. 12. Scleroderma-A PA chest radio-
graph reveals decreased lung volumes, most
pronounced on the left; pleuro-pericardial
adhesions, and bibasilar interstitial disease.
The main pulmonaryartery segment is promi-
nent, and pulmonary artery pressure measure-
ments were elevated.
radiograph is an interstitial reticular pattern (Fig. 12) particularly affecting the lung
bases [119]. These basilar changes are due mainly to the recurrent aspiration
pneumonia that occurs and in part to the primary disease process. As the disease
progresses, the pulmonary infiltration becomes more dense, with subsequent honey-
combing and cyst formation. The cysts are most often subpleural in the basal and
paravertebral areas and are usually bilateral. Although they tend to be small (5 mm
or less in diameter), large cysts may occur and rupture, which produces a pneumo-
thorax [2,119,138]. Other findings include micronodulation, increased vascular
markings, and pulmonary edema [2,120]. Disseminated pulmonary calcification or
calcification of the soft tissue of the thorax may be seen on chest radiograph. The
latter may also demonstrate the presence of pleural thickening, pleural effusion, and
signs of pulmonary hypertension secondary to sclerodermatous lungdisease (Fig. 12)
[119,120]. Disturbance of esophageal motility may result in retention of food and
recurrent aspiration pneumonia.
Pathologic Findings Pathologic changes in the lungs frequently occur with or
without clinical abnormalities [120,126,139-141]. In an autopsy study, Weaver and
co-workers [141] found pulmonary abnormalities in all 28 cases ofscleroderma. The
most prominent finding was a progressive and nonspecific bilateral interstitial
fibrosis of the lower lobe with bronchiolectasis and cyst formation. Marked intimal
thickening by loose myxomatous connective tissue occurred in small pulmonary
arteries and arterioles. Norton and Nardi emphasized that involvement of the
arterioles and capillary bed in many tissues, particularly in the lungs and kidneys, is
the basis of scleroderma [139]. They concluded that scleroderma must be regarded as
a vascular disease. It is clear that the pulmonary vascular lesions are not merely an
extension of interstitial fibrosis, since many scleroderma lungs have areas of severe
interstitial fibrosis without arterial lesions, as well as areas of vascular changes
without interstitial disease [140]. Other thoracic pathology in patients with sclero-
derma includes pleural thickening or effusion, cardiomegaly, vascular congestion,
pulmonary edema, enlarged pulmonary arteries, and pneumonitis [119].
Therapy and Prognosis
Unfortunately, no effective therapy has been found for cases of scleroderma
[129,146]. There is no evidence that corticosteroids or cytotoxic agents alter outcome
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TABLE 4
Differential Diagnosis of Chest Radiographic Findings in Pulmonary Renal Syndromes
Lympho- Systemic
Chest Good- Wegener's matoid Churg- Lupus
Radiographic pasture's Granulo- Granulo- Strauss Erythema- Sclero-
Characteristics Syndrome matosis matosis Syndrome tosus derma
Alveolar + + + + + + + + + + +
Filling pattern
Interstitial
infiltrates ++ ++ ++ ++ ++ +++
Large nodular
lesions 0 + + + + + 0 0 0
Cavitary lesions 0 + + + + 0 0 0
Hilar adenopathy 0 + + 0 + 0
Mediastinal
adenopathy 0 0 + 0 + 0
Pleural effusion 0 + + + 0 +++ +
Atelectasis + + + + + + + + + +
Pulmonary
hypertension 0 + 0 + + + +
Cardiac
enlargement + + + + + 0 + + + +
++
+
Predominant finding
Frequently present
Rarely present
Not described
in this disease. Prognosis is unfavorable, and survival in scleroderma appears to
depend primarily on the degree of involvement of the heart, kidneys, and lungs
[119,120,125].
DIFFERENTIAL DIAGNOSIS OF THE PULMONARY RENAL SYNDROMES
Distinguishing features of the individual pulmonary renal syndromes are outlined
in Tables 2,3,4 and 5. In general, lung or renal biopsy is required to distinguish most
TABLE 5
Differential Diagnosis of Pulmonary Renal Syndromes: Therapeutic Implications
Lympho- Systemic
Good- Wegener's matoid Churg- Lupus
pasture's Granulo- Granulo- Strauss Erythema- Sclero-
Syndrome matosis matosis Syndrome tosus derma
Corticosteroids May be May be May be Useful Useful Not
useful useful useful useful
tempo-
rarily
Cytotoxic agents May be Very useful May be Unproven May be Not
useful (Cytoxan useful benefit useful useful
treatment
of choice)
Plasmaphoresis May be Not useful Not useful Not Not Not
tran- useful proven useful
iently useful
helpful
Bronchodilators Limited Limited Limited May be Not Not
useful- useful- useful- useful useful useful
ness ness ness
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of the pulmonary renal syndromes from each other. However, in some cases the
diagnosis may be evident without tissue confirmation. In patients with skin changes
characteristic of scleroderma biopsy may not be required. Similarly, patients with
Wegener's granulomatosis who present with hemoptysis, hematuria, multinodular
and/or cavitating lung lesions, and nasal or sinus lesions are distinguishable from
patients with Goodpasture's syndrome. The latter generally do not have cavitating,
large nodular lung lesions, and nasal or sinus lesions (Tables 2,3).
A patient with frank hemoptysis, hematuria with renal failure, and a diffuse,
bilateral alveolar filling process is most likely to have Goodpasture's syndrome.
Rarely, SLE is associated with this clinical constellation, including hemoptysis.
However, the LE cell preparation and/or antinuclear factor are positive in SLE but
negative generally in Goodpasture's syndrome (Tables 2,3,4).
Tissue is required in most cases to distinguish lymphomatoid granulomatosis from
Wegener's granulomatosis. However, Churg-Strauss syndrome can be differentiated
from the other five pulmonary renal syndromes by the presence ofperipheral blood
eosinophilia and wheezing (Tables 3,4).
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